Toronto, September 11, 2014 – The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), regarding a September 11, 2014 media report related to United States Food and Drug Administration inspections:
“The Canadian Generic Pharmaceutical Association (CGPA) is aware of media reports regarding regulatory enforcement activities of the United States Food and Drug Administration (FDA) affecting brand-name and generic pharmaceutical manufacturers in Canada.
Health Canada’s regulatory requirements for the review and approval of generic pharmaceutical products are among the world’s most stringent. This is also true in regard to Health Canada’s standards for Canadian facilities in which brand-name and generic pharmaceutical products are produced.
As the international regulatory environment for pharmaceutical products continues to evolve, members of CGPA remain committed to taking all necessary steps to continue to provide Canadians with the highest quality pharmaceutical products in the world.”
About the Canadian Generic Pharmaceutical Association
The Canadian Generic Pharmaceutical Association (CGPA) represents Canada’s generic pharmaceutical industry. The industry plays an important role in controlling health-care costs in Canada. Generic drugs are dispensed to fill 66 per cent of all prescriptions but account for account for only 24 per cent of the $22-billion Canadians spend annually on prescription medicines.